Diagnostics and infection-control businesses play an important role across hospitals, clinics and other healthcare settings. ImpediMed Limited (ASX:IPD), Nanosonics Limited (ASX:NAN) and Lumos Diagnostics Holdings Limited (ASX:LDX) operate across different parts of this market, ranging from lymphoedema monitoring and medical-device disinfection to rapid respiratory testing.

Their financial positions also differ significantly. ImpediMed remains loss-making while expanding recurring revenue, Nanosonics has an established profitable Business and substantial cash resources, while Lumos is building product revenue around FebriDx as it develops its US commercial presence.

Healthcare Technology Outlook

Healthcare technology companies often need to move through several stages before commercial scale is achieved. Regulatory clearance, reimbursement and hospital procurement can all influence the speed at which an approved product converts into recurring revenue.

For investors assessing smaller healthcare companies, financial performance and cash resources are particularly important. Revenue growth needs eventually to translate into operating leverage, while companies still recording losses may require additional funding if commercial expansion takes longer than expected.

ImpediMed Limited (ASX:IPD)

Company Profile

ImpediMed develops the SOZO bioimpedance spectroscopy platform, which is used to monitor fluid and tissue composition, including for early detection of lymphoedema in cancer patients.

The company operates primarily through a subscription-based model, allowing healthcare providers to licence the platform and generating Recurring Revenue as the installed base expands.

FY2026 Financial Performance

ImpediMed reported FY2026 revenue of AUD 14.6 million.

The company recorded a net loss of AUD 24.9 million and operating cash outflow of AUD 17.9 million.

Annual recurring revenue stood at AUD 14.4 million at 30 June 2026.

ImpediMed ended the period with AUD 15.3 million of cash after completing additional Capital funding during 2026 and reducing part of its Debt facility.

Management has also implemented annualised cost reductions of at least AUD 5 million as it works toward its longer-term operating cash-flow breakeven objective.

Outlook and Risks

ImpediMed remains focused on converting broader reimbursement coverage and healthcare-system relationships into additional SOZO placements and recurring revenue.

Financially, the main issue remains the gap between revenue and operating expenditure. Continued cost discipline and commercial growth will be needed to reduce cash consumption.

Additional funding could remain a consideration if progress toward breakeven takes longer than anticipated.

Nanosonics Limited (ASX:NAN)

Company Profile

Nanosonics develops infection-control technologies used in healthcare environments.

Its established trophon platform provides high-level disinfection for ultrasound probes, supported by recurring consumable revenue from a large installed base.

The company is also developing CORIS, an automated technology designed for the cleaning of flexible endoscopes.

FY2026 Financial Performance

Nanosonics reported FY2026 revenue of AUD 203.9 million.

Recurring revenue reached AUD 149.2 million, while capital revenue contributed AUD 54.7 million.

The global installed base reached 39,230 units at the end of the period.

Gross Margin was 76.9%, while reported EBIT was AUD 16.0 million.

The company finished FY2026 with AUD 155.2 million in cash and no debt.

Nanosonics also completed an AUD 20 million on-market share buyback during FY2026 and subsequently announced a further buyback of up to AUD 40 million for FY2027.

FY2027 Outlook

Nanosonics has guided to FY2027 constant-currency revenue of AUD 220 million to AUD 228 million.

Gross margin is expected to range between 74% and 76%, while operating expenditure is expected to increase as the company invests in the commercial rollout of CORIS.

The trophon installed base and recurring consumables remain the foundation of the business, while CORIS represents the next potential growth platform.

Risks

Higher Investment in CORIS could weigh on near-term Earnings and margins before the new platform reaches commercial scale.

The company also faces freight and Tariff pressures and must continue generating growth from its established trophon franchise.

Execution of the CORIS rollout will therefore be an important Factor through FY2027.

Lumos Diagnostics Holdings Limited (ASX:LDX)

Company Profile

Lumos Diagnostics operates across point-of-care diagnostic products and contract diagnostic services.

Its main commercial product is FebriDx, a rapid fingerstick blood test designed to help distinguish bacterial from non-bacterial acute respiratory infections.

The company also provides diagnostic test development and Manufacturing services to external customers.

FY2026 Financial Performance

Lumos reported unaudited FY2026 revenue of USD 13.2 million.

FebriDx product revenue reached USD 3.9 million, while total products revenue was USD 4.3 million.

Services revenue contributed USD 8.9 million.

Lumos ended FY2026 with USD 15.4 million of cash.

For the first half of FY2026, the company reported a net loss of USD 4.88 million and an adjusted EBITDA loss of USD 1.38 million.

The company also completed additional Equity funding during 2026 to support commercial expansion.

Outlook and Risks

Lumos is focused on expanding FebriDx adoption in the United States following regulatory and reimbursement progress.

The upcoming respiratory season could provide a clearer indication of commercial Demand as the test reaches a broader range of healthcare settings.

However, Lumos remains loss-making and its US product strategy relies significantly on external distribution arrangements. Revenue from its services operation has also softened, meaning FebriDx growth will be increasingly important to the overall financial profile.

Risks to Watch

ImpediMed's main Financial Risk is continued cash consumption while commercial placements develop. Revenue and recurring income need to grow alongside the company's cost-reduction programme.

Nanosonics has the most established financial position of the three, although increased spending on CORIS and pressure on gross margin may affect near-term earnings.

Lumos remains in an earlier commercial stage, with future performance depending increasingly on FebriDx adoption while it continues to manage operating losses.

What Investors May Watch Through the Rest of 2026

For ImpediMed, attention may remain on recurring revenue growth, new SOZO placements and progress toward reducing operating cash outflow.

For Nanosonics, investors may monitor the trophon installed base, recurring consumable revenue and the initial commercial rollout of CORIS.

For Lumos, FebriDx order activity and product revenue during the northern-hemisphere respiratory season may provide a clearer indication of commercial traction.

Across the three companies, financial discipline remains important as healthcare technology businesses balance commercial investment against the pace of customer adoption.